Clinical Trial Update: A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus) [Phase 2]

View source ↗

Summary

Noema Pharma AG completed a Phase 2 efficacy study of NOE-105 for Childhood-Onset Fluency Disorder; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood-onset Fluency Disorder

Drugs mentioned

• NOE-105

Snippet

Sponsor: Noema Pharma AG | Conditions: Childhood-Onset Fluency Disorder | Phase 2 | Status: COMPLETED | Results posted: 2026-02-03